- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01648972
Gastrografin in Postoperative Ileus (GAP)
Randomised Double-blind Placebo-controlled Trial of Gastrografin in the Therapeutic Management of Prolonged Postoperative Ileus Following Elective Surgery.
After abdominal surgery there is a period of unavoidable dysfunction of the gut. During this time patients are often unable to eat and drink, and do not pass any flatus or stool. Though this resolves within a few days for most, there are a significant number (around 30%) who go on to have a prolonged period of this dysfunction known clinically as postoperative ileus. It has been clearly shown that this group of patients have worse health outcomes and spend a longer time in hospital.
The aim of this study is to trial a drug - gastrografin - in the management of prolonged postoperative ileus. Gastrografin is safe, economical, readily available, and has been used with great success in the similar condition of bowel obstruction. It is predicted that gastrografin will shorten the duration of a prolonged postoperative ileus, thus affording affected patients a better outcome from surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
AKL
-
Auckland, AKL, New Zealand, 1010
- Auckland City Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years.
- Current inpatient following elective laparoscopic or open surgery.
- Classified as having prolonged postoperative ileus.
- Able to understand risks/benefits of the study.
- Able to give informed consent.
Exclusion Criteria:
- Pregnancy.
- ASA of 4 or greater.
- Previous allergic reaction to gastrografin or iodinated contrast agents.
- Manifest hyperthyroidism.
Study Plan
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Experimental: Gastrografin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Time from diagnosis (and administration of study drug) to resolution of prolonged postoperative ileus.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Length of hospital stay (days)
Time Frame: Days
|
Days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UOA-ggRCT1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prolonged Postoperative Ileus
-
University of Lausanne HospitalsCompletedNasogastric Tube | Ileus PostoperativeSwitzerland
-
Erzincan Military HospitalCompletedPostoperative IleusTurkey
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenCompleted
-
University Hospital, GhentUniversity GhentTerminated
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
Seoul National University HospitalCompletedPostoperative IleusKorea, Republic of
-
Alberta Children's HospitalWithdrawnPostoperative IleusCanada
-
University Hospital, AngersCompleted
-
Hospital Universitari de BellvitgeCompleted
-
Chinese University of Hong KongUnknownPostoperative IleusChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States